The Cancer Metabolism Based Therapeutics Market is Estimated to Witness High Growth

Cancer metabolism based therapeutics are drugs that target specific alterations in the metabolism of cancer cells to kill them or stop their growth. Cancer cells rely more heavily on certain metabolic pathways compared to normal cells to meet their high energy and biosynthetic demands. Targeting these metabolic vulnerabilities provides opportunities for selective anti-cancer therapies with less toxicity. The global cancer metabolism based therapeutics market is estimated to be valued at US$ 210.2 billion in 2023 and is expected to exhibit a CAGR of 95% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity:
Targeting Metabolic Pathways
There is significant opportunity to develop more cancer metabolism based therapeutics that can target specific metabolic pathways in cancer cells such as glycolysis, glutaminolysis, and fatty acid synthesis. Inhibiting these pathways essential for cancer cell survival presents opportunities for effective targeted cancer therapies. Ongoing research aims to identify more key metabolic differences between cancer and normal cells that can be exploited. Developing drugs against these metabolic vulnerabilities can significantly improve cancer treatment outcomes with fewer side effects compared to traditional chemotherapy.

Porter’s Analysis
Threat of new entrants: The presence of stringent regulations for approval of new drugs and significant capital investment required for R&D activities creates barriers for new entrants in the cancer metabolism based therapeutics market.
Bargaining power of buyers: The bargaining power of buyers is low as the availability of very few alternatives and life threatening nature of cancer makes patients opt for the available treatments.
Bargaining power of suppliers: The presence of a significant number of pharmaceutical companies and academic/research institutes engaged in cancer metabolism based drug research increases the bargaining power of suppliers.
Threat of new substitutes: The threat of substitutes is low as there aren’t many effective substitute treatment options available for cancer currently.
Competitive rivalry: The competitive rivalry is high owing to the presence of major players investing heavily in R&D to develop novel drugs and targets.

SWOT Analysis
Strength: Growing research in cancer metabolism, development of advanced biomarkers and screening tools, high unmet needs.
Weakness: High failure rate of drugs in clinical trials, resistance development, high investment requirements.
Opportunity: Emerging Asian markets, collaborations between industry and academia, targeting new pathways and combinations.
Threats: Stringent regulations, reimbursement issues, alternative therapies.

Key Takeaways
The global Cancer Metabolism Based Therapeutics market is expected to witness high growth over the forecast period of 2023 to 2030. By 2024, the market size is projected to reach US$ 210.2 Bnregistering a CAGR of around 95%.

Regional analysis shows that North America dominates currently due to presence of majority of key players and research centers. However, Asia Pacific is expected to grow at fastest rate owing to rising cancer incidence, improving healthcare infrastructure and increasing investments from international players.

Key players operating in the Cancer Metabolism Based Therapeutics market are Calithera Biosciences, Inc., Celgene Corporation, Agios Pharmaceutical, Rafael pharmaceuticals, 3-V Biosciences, and AstraZeneca. Calithera Biosciences is a clinical-stage biopharmaceutical company focused on developing novel small molecule drugs targeting tumor cell metabolism to treat cancer. Celgene Corporation focuses on developing treatments for cancer and inflammatory disorders through a portfolio of small molecule and biologic therapies.